Semaglutide Archives - Medical Conferences

AHA Names 7 Cardiovascular Research Breakthroughs in 2024

19 December 2024 11:40

Semaglutide improves outcomes for patients with obesity and HS

Presented By

Dr Daniel Lyons, St Vincent’s University Hospital, Ireland

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:14

The unfavourable role of obesity in psoriatic disease

Presented By

Prof. Ulrich Mrowietz, University Medical Center Schleswig-Holstein, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:13

Effects of semaglutide on MACE irrespective of HF status

Presented By

Prof. John Deanfield, University College London, UK

Trial

SELECT

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 17:15

Semaglutide improves renal outcomes in overweight/obese participants with cardiovascular disease and no diabetes

Presented By

Prof. Helen M. Colhoun, The University of Edinburgh, United Kingdom

Trial

Phase 3, SELECT

Conference

ERA 2024

Type

News article

20 June 2024 19:19

STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes

Presented By

Prof. Mikhail Kosiborod, Saint Luke's Mid America Heart Institute, MO, USA

Trial

Phase 3, STEP-HFpEF DM

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:20

Successful results for semaglutide in the highly anticipated SELECT trial

Presented By

Dr Michael Lincoff, Cleveland Clinic, USA

Trial

Phase 3, SELECT

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:37

Top 10 medical breakthroughs in 2023

Expert

Dr Alex McDonald (Board member, Physician’s Weekly) and Dr Rachel Giles (Medical Science Officer, Medicom Medical Publishers)

18 December 2023 15:29

STEP-HFpEF: Semaglutide safe and efficacious in HFpEF plus obesity

Presented By

Dr Mikhail Kosiborod, University of Missouri, USA

Trial

Phase 3, STEP-HFpEF

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:01